title: Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis.
abstract: OBJECTIVE
  To compare dexamethasone (DEX) intravitreal implant effect in non-vitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis.
  
  
  METHODS
  Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology.
  
  
  RESULTS
  Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12-24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P=NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P=NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P=0.025) to 12th month (P=0.013). Vitreous haze score improved in both groups since first month and showed no differences (P=0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5-6). Ocular hypertension (47.6%) was the most common adverse event.
  
  
  CONCLUSIONS
  DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring.
authors.affiliation: 1] Institut Clínic d'Oftalmologia, Hospital Clínic de Barcelona, Barcelona, Spain [2] Universitat de Barcelona, Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Pelegrín
authors.affiliation: 1] Institut Clínic d'Oftalmologia, Hospital Clínic de Barcelona, Barcelona, Spain [2] Universitat de Barcelona, Barcelona, Spain.
authors.forename: M S
authors.initials: MS
authors.lastname: de la Maza
authors.affiliation: Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Barcelona, Spain.
authors.forename: B
authors.identifier: 0000000309419134
authors.initials: B
authors.lastname: Molins
authors.affiliation: 1] Biostatistics and Data Management Core Facility, IDIBAPS, (Hospital Clinic), Barcelona, Spain [2] Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Ríos
authors.affiliation: 1] Institut Clínic d'Oftalmologia, Hospital Clínic de Barcelona, Barcelona, Spain [2] Universitat de Barcelona, Barcelona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Adán
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D004341:Drug Evaluation; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D019233:Retreatment; D014605:Uveitis / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity / Q000187:drug effects; D014821:Vitrectomy
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone